ALK Inhibitors for Treatment of ALK-Negative Cancer and Plasma Cell-Mediated Diseases
ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Summary
The European Patent Office published patent application EP4051288A1, filed by Universitetet I Oslo, covering ALK inhibitors for treating ALK-negative cancers and plasma cell-mediated diseases. The invention relates to therapeutic applications of ALK inhibitors beyond their typical indication. Publication date: March 25, 2026. This grant affects pharmaceutical companies developing cancer therapeutics in Europe.
What changed
The EPO granted patent EP4051288A1 to Universitetet I Oslo, covering ALK inhibitors for ALK-negative cancer and plasma cell-mediated diseases. Named inventors include Fredrik Hellem Schjesvold and Christoph Driessen among others. The patent specifies A61K 31/66 and related pharmaceutical compositions. Designated states cover all EPO member states including Germany, France, UK, and other EU jurisdictions.\n\nPharmaceutical companies developing ALK inhibitors or treating plasma cell diseases should review this IP position to assess freedom-to-operate in the European market. Drug manufacturers in the oncology space may need to consider licensing negotiations or design-around strategies for any overlapping therapeutic claims.
Source document (simplified)
ALK INHIBITORS FOR TREATMENT OF ALK-NEGATIVE CANCER AND PLASMA CELL-MEDIATED DISEASES
Publication EP4051288A1 Kind: A1 Mar 25, 2026
Applicants
Universitetet I Oslo
Inventors
FARHAN, Hesso, MUNTHE, Ludvig, TASKEN, Kjetil, SKÅNLAND, Sigrid, GILIBERTO, Mariaserena, HELLEM SCHJESVOLD, Fredrik, DRIESSEN, Christoph, BESSE, Lenka, BESSE, Andrej
IPC Classifications
A61K 31/66 20060101AFI20210510BHEP A61K 31/4545 20060101ALI20210510BHEP A61K 31/496 20060101ALI20210510BHEP A61K 31/50 20060101ALI20210510BHEP A61K 31/506 20060101ALI20210510BHEP A61K 31/5377 20060101ALI20210510BHEP A61P 35/00 20060101ALI20210510BHEP A61K 31/00 20060101ALI20210510BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.